Drugs / Cyclophosphamid
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT06238245 | Feb 2024 → Dec 2025 | graft versus host disease, hematopoietic and lymphoid cell neoplasm | Beijing 302 Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03852407 | Feb 2019 → Nov 2033 expected | Hodgkins lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia +2 | University of Liege | Recruiting | No outcome recorded |
| Phase 2 | NCT00590447 | Dec 2006 → Dec 2014 | post-transplant lymphoproliferative disease | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06108739 | Nov 2023 → Dec 2024 | hematopoietic and lymphoid cell neoplasm | Peking University People's Hospital | Terminated | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05990985 | Sep 2023 → Aug 2024 overdue | diffuse large B-cell lymphoma | The First Hospital of Jilin University | Not yet recruiting | No outcome recorded |
| Comparator or background therapy12 trials | ||||||
| Phase 1 | NCT06027853 Background | Sep 2023 → Aug 2026 overdue | acute myeloid leukemia | Zhejiang University | Recruiting | No outcome recorded |
| Phase 1 | NCT05987696 Background | Jul 2023 → Jan 2025 | acute myeloid leukemia | Institute of Hematology & Blood Diseases Hospital, China | Completed | No outcome recorded |
| Phase 1 | NCT05665075 Background | Dec 2022 → Dec 2023 | acute myeloid leukemia | Zhejiang University | Unknown | No outcome recorded |
| Phase 1 | NCT05665114 Background | Dec 2022 → Dec 2023 | acute myeloid leukemia | Zhejiang University | Unknown | No outcome recorded |
| Phase 1 | NCT05601830 Background | Oct 2022 → Jun 2023 | hematopoietic and lymphoid cell neoplasm | Institute of Hematology & Blood Diseases Hospital, China | Terminated | No outcome recorded |
| Phase 1 | NCT05601466 Background | Mar 2022 → Apr 2023 | acute myeloid leukemia | Institute of Hematology & Blood Diseases Hospital, China | Terminated | No outcome recorded |
| Phase 1 | NCT05379647 Background | Nov 2021 → Jun 2024 | B-cell acute lymphoblastic leukemia | Zhejiang University | Unknown | No outcome recorded |
| Phase 1 | NCT04706936 Background | Apr 2021 → Oct 2023 | refractory plasma cell neoplasm | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 1/2 | NCT07255664 Background | Nov 2025 → Apr 2027 expected | colorectal cancer, prostate cancer | CuraCell TX AB | Recruiting | No outcome recorded |
| Phase 2 | NCT06047171 Background | Sep 2023 → Jun 2027 expected | rapidly progressive glomerulonephritis | Alentis Therapeutics AG | Recruiting | No outcome recorded |
| Phase 2 | NCT01690325 Background | Sep 2012 → Nov 2016 | breast cancer | West German Study Group | Terminated | No outcome recorded |
| Phase 2/3 | NCT07712588 Background | Sep 2027 → Jan 2031 expected | diffuse large B-cell lymphoma | Dizal Pharmaceuticals | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cyclophosphamid | “Cyclophosphamid 750 mg/m2, adriamycine 50 mg/m2 and vincristine 1.4mg/m2, IV and prednisone 50mg/m2, PO every 3 weeks at days 50, 72, 94 and 116.” NCT00590447 ↗16“Drug: Cyclophosphamid Lympho-conditioning Agent” NCT06027853 ↗ |
| Route | Intravenous | “Cyclophosphamid 750 mg/m2, adriamycine 50 mg/m2 and vincristine 1.4mg/m2, IV and prednisone 50mg/m2, PO every 3 weeks at days 50, 72, 94 and 116.” NCT00590447 ↗ |